

1 **Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2**  
2 **infection and vaccination**

3  
4 Anne Hege Aamodt<sup>1,2</sup>, Thor Ueland<sup>3,4,5</sup>, Marion I. Boldingh<sup>1</sup>, Burcu Bezgal<sup>1</sup>, Maria Argren<sup>1,4</sup>,  
5 Cecilia Adele Dunne<sup>4</sup>, Kari Otterdal<sup>3</sup>, Ida Gregersen<sup>3</sup>, Vigdis Bjerkeli<sup>3,4</sup>, Annika Elisabet  
6 Michelsen<sup>3,4</sup>, Andreas Husøy<sup>2,6</sup>, Åse Hagen Morsund<sup>7</sup>, Kristina Devik<sup>1,8</sup>, Anne Christine  
7 Poole<sup>9</sup>, Kristine Gjendemsjø<sup>10</sup>, Katrin Schlüter<sup>11</sup>, Sara Maria Mathisen<sup>11</sup>, Mari Aalstad-  
8 Johansen<sup>12</sup>, Thor Skattør<sup>1,4,13</sup>, Julie Sønnervik<sup>14</sup>, Birgitte Boye<sup>15,16</sup>, Trine Haug Popperud<sup>1</sup>,  
9 Einar August Høgestøl<sup>1,4</sup>, Hanne Flinstad Harbo<sup>1,4</sup>, Fridtjof Lund-Johansen<sup>4,17</sup>, Pål  
10 Aukrust<sup>3,4,18</sup>, Erling Tronvik<sup>2,6</sup>, Tuva Børresdatter Dahl<sup>3</sup>, Bente E. Halvorsen<sup>3,4,19</sup>

11 <sup>1</sup>Department of Neurology, Oslo University Hospital, Oslo, Norway

12 <sup>2</sup>Department of Neuromedicine and Movement Science, the Norwegian University of Science  
13 and Technology, Trondheim, Norway

14 <sup>3</sup>Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo,  
15 Norway

16 <sup>4</sup>Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

17 <sup>5</sup>Thrombosis Research Center (TREC), Division of internal medicine, University Hospital of  
18 North Norway, Tromsø, Norway

19 <sup>6</sup>Department of Neurology of Clinical Neurophysiology, St. Olav Hospital, Trondheim,  
20 Norway

21 <sup>7</sup>Department of Neurology, Molde Hospital, Molde, Norway

22 <sup>8</sup>Department of Neurology, Namsos Hospital, Molde, Norway

23 <sup>9</sup>Oslo Headache Centre, Oslo, Norway

24 <sup>10</sup>Sandvika Neuro Centre, Sandvika, Norway

25 <sup>11</sup>Department of Neurology, Stavanger University Hospital, Stavanger, Norway

26 <sup>12</sup>Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway

27 <sup>13</sup>Department of Radiology, Oslo University Hospital, Oslo, Norway

28 <sup>14</sup>Hodeverket, Sandnes, Norway

29 <sup>15</sup>Unit Psychosomatic medicine and CL psychiatry, Oslo University Hospital, Oslo, Norway

30 <sup>16</sup>Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway

31 <sup>17</sup>Department of Immunology, Oslo University Hospital, Oslo, Norway.

32 <sup>18</sup>Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo,  
33 Norway

34 <sup>19</sup>Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's  
35 Hospital, Harvard Medical School, Boston, MA, USA

36

37

38 **Abstract**

39 **Background and objectives:** New onset persistent headache has been reported following  
40 acute COVID-19 disease and to some degree also after SARS-CoV-2 vaccination. Still, the  
41 mechanisms for these headache types are unclear. The purpose of this study was to assess  
42 levels of amyloid related biomarkers in patients with persistent headache after COVID-19 and  
43 SARS-CoV-2 vaccine.

44 **Methods:** In this prospective observational cohort, patients with severe headache as the  
45 dominating symptom after COVID-19 disease (n=29) and SARS-CoV-2 vaccination (n=31),  
46 had neurological assessments with reassessments after 6 months. Plasma levels of amyloid  
47 precursor protein (APP), pregnancy zone protein (PZP), cathepsin L1 (CTSL) and serum  
48 Amyloid A (SAA1) were measured by ELISA in relation to levels in healthy controls (n=16).

49 **Results:** We found a strong and persistent upregulation of APP in patients with headache  
50 after COVID-19 as compared to the two other groups. At both inclusion and after 6 months  
51 APP levels were also increased in those with accompanying cognitive symptoms. In contrast,  
52 plasma levels of PZP were elevated in both headache groups as compared to healthy controls  
53 at inclusion and after 6 months follow-up, but with no relation to cognitive symptoms. CTSL  
54 was only elevated in those with COVID-19 associated headache at baseline, whereas SAA1  
55 showed levels comparable in all groups.

56 **Conclusion:** Altered plasma levels of soluble markers potentially reflecting changes in  
57 amyloid processing was found in patients with persistent headache after SARS-CoV-2  
58 vaccine and particular in those with persistent headache after COVID-19 disease where we  
59 also found some association with cognitive symptoms.

60

61 NCT04576351

62 NCT05235776

63

64 **What is already known on this topic**

65 New onset persistent headache occurs in a subset of individuals after COVID-19 and to some  
66 extent after SARS-CoV-2 vaccine. However, the pathophysiological mechanisms are  
67 unknown.

68

69 **What this study adds**

70 There was high disability with only modest improvement after 6-month follow-up.

71 Altered plasma levels of soluble markers that potentially could reflect changes in amyloid  
72 processing was found in patients with persistent headache after SARS-CoV-2 vaccine and  
73 particular in those with persistent headache after COVID-19 disease with association to  
74 cognitive symptoms.

75

76 **How this study might affect research, practice or policy**

77 Our data point to plausible mechanism of amyloid processing and neuroinflammation in  
78 relation to COVID-19 and SARS-CoV-2 vaccine.

79

80

81

## 82 **Introduction**

83 During the COVID-19 pandemic, headache emerged as an important health issue, increasing  
84 the burden of headache disorders.<sup>1,2</sup> Both SARS-CoV-2 infection and, although to a lesser  
85 degree, SARS-CoV-2 vaccination, induced headache as a secondary headache disorder as  
86 well as negatively impact already existing primary headache disorder.<sup>1,3</sup> Thus, those with  
87 primary headache disorder experience headache in the acute phase of COVID-19 and after  
88 vaccination more often than other SARS-CoV-2-infected or vaccinated individuals.<sup>1</sup>  
89 Approximately one in five patients who present headache during the acute phase of COVID-  
90 19, get persistent headache, often with accompanying symptoms including cognitive  
91 symptoms and fatigue.<sup>1</sup> Also, a subset of individuals with headache attributed to SARS-CoV-  
92 2 vaccinations develop long lasting headaches.<sup>1,3</sup> Furthermore, in patients with primary  
93 headache disorders, SARS-CoV-2 vaccination and in particular an acute SARS-CoV-2  
94 infection worsened their chronic headache burden.<sup>3</sup> The mechanisms for persistent headaches  
95 after SARS-CoV-2 infection or vaccines are, however, unknown. One proposed mechanism is  
96 persistent immune activation and inflammation triggered by SARS-CoV-2 or vaccination.<sup>4,5</sup>  
97 with the trigeminovascular system as a potential target.<sup>1</sup> Additionally, the inflammatory  
98 responses during acute COVID-19 disease, involving the release of prostaglandins,  
99 interleukin (IL)-6 and other inflammatory cytokines could increase blood-brain barrier  
100 permeability leading to neuroinflammation with accompanying headache.<sup>6,7</sup>

101 Serum Amyloid A (SAA1), an acute phase protein and systemic marker of  
102 inflammation, was early reported as a biomarker of poor prognosis in COVID-19.<sup>8</sup> Recently,  
103 amyloid precursor protein (APP), a membrane protein considered to play a main role in  
104 Alzheimer disease pathology,<sup>9</sup> was described as a new receptor for SARS-CoV-2 infection  
105 and revealed a previously unknown mechanistic insight into COVID-19 related  
106 neuropathological sequelae.<sup>10</sup> Moreover, Pregnancy Zone Protein (PZP), originally known as  
107 a broad-spectrum immune-suppressive protein that suppresses T-cell function during  
108 pregnancy to prevent foetal rejection, has also been proposed as a biomarker for various  
109 inflammatory disorders,<sup>11,12</sup> including the prognosis of COVID-19 disease.<sup>13</sup> With relevance  
110 to CNS involvement, serum levels of PZP were higher in women with pre-symptomatic  
111 Alzheimer's disease.<sup>14</sup> Furthermore, Cathepsin L1 (CTSL), a lysosomal cysteine protease that  
112 plays a major role in intracellular protein catabolism, has been demonstrated to enhance  
113 SARS-CoV-2 virus entry, at least in pre-clinical models,<sup>15</sup> and interestingly, CTSL has also  
114 been suggested to be involved in the degradation of certain amyloid fibrils.<sup>16</sup> To this end,  
115 however, circulating levels of these biomarkers (i.e., SAA1, APP, PZP, and CTSL) in patients

116 with persistent headaches after SARS-CoV-2 infection or vaccination, with or without  
117 headache during the acute phase of COVID-19 or immediately after vaccination, have not  
118 been reported.

119 In the present study, with the aim to give novel insight into the pathological  
120 mechanisms leading to persistent headache following COVID-19 and SARS-CoV-2  
121 vaccination, we compared plasma levels of APP, PZP, CTSL, and SAA-1 in patients with  
122 persistent headache after SARS-CoV-2 infection or vaccination compared with levels in  
123 healthy controls without headaches. The levels of these molecules were also related to the  
124 presence of accompanying fatigue or cognitive symptoms, and in the COVID-19 group, the  
125 need for hospitalization during the acute infection.

126

## 127 **Methods**

128 In this prospective observational cohort study performed at Norwegian neurological  
129 departments and led by Oslo University Hospital, Oslo, Norway, clinical characteristics and  
130 blood biomarker profiles were assessed in patients with severe headaches for a minimum of  
131 six months after COVID-19 or SARS-CoV-2 vaccination and compared to healthy controls.  
132 The inclusion period lasted from September 2020 to June 2023.

133

### 134 **Study population and clinical assessments of the participants**

135 The subgroup with **persistent headache after COVID-19 (n=29)** was recruited from the  
136 cohort of 155 individuals aged  $\geq 18$  years with persistent neurological symptoms 6 months  
137 after COVID-19 infection in the Norwegian observational multicentre study of nervous  
138 system manifestations and sequelae after COVID infection (NNC), a sub study of the  
139 ENERGY study led by European Academy of Neurology.<sup>17</sup> The subgroup with **persistent**  
140 **headache after SARS-CoV-2 vaccine (n=31)** were participants in the Norwegian  
141 observational multi-centre study CovaxHEAD: New-onset severe headache after COVID-19  
142 vaccine (NCT05235776) - a parallel study led by the same team as the NNC study collecting  
143 comparable variables.

144 Inclusion criteria for both subgroups were age  $\geq 18$  years and new onset severe  
145 headache or severe worsening of pre-existing headache within one week after SARS-CoV-2  
146 infection or vaccination. The degree of headache severity had to be so pronounced that the  
147 headaches were daily or almost daily and had resulted in significant disability or sick leave  
148 and still were the dominant symptom at 6-month follow-up. Exclusion criteria were short-  
149 lasting headaches, no follow-up assessments, or where other diagnoses were considered a

150 better explanation for their symptoms (e.g. infections including COVID-19, head trauma, or  
151 somatoform disorders). Participants with COVID-19 disease who reported their headaches  
152 starting after SARS-CoV-2 vaccination were not included. Thus, none in this COVID-19  
153 subgroup had SARS-CoV-2 vaccine induced headache.

154 For both headache groups, an inclusion criterion was available plasma samples that  
155 could be used in biomarker analyses. The clinical data, including the headache diagnoses,  
156 were reviewed by a senior neurologist with headache expertise (AHA).

157 The **control group** consisted of healthy individuals (n=16) based on disease history  
158 without migraine or any other disabling headache disorders and who had never experienced  
159 neurological symptoms after SARS-CoV-2 vaccine or COVID-19. Additional inclusion  
160 criteria in the control group were no immunological disorders or use of immunosuppressive  
161 drugs. The healthy controls, consisting of 8 men and 8 women, mean age 40.6 years (SD  
162 11.2), were recruited from local advertisements at Oslo University Hospital.

### 163 **Blood sampling protocol**

164 Peripheral venous blood was drawn into pyrogen-free blood collection tubes with  
165 ethylenediamine tetraacetic acid (EDTA) as an anticoagulant, immediately immersed in  
166 melting ice and centrifuged at 4°C 2500 × g for 20 minutes within 60 minutes to obtain  
167 platelet-poor plasma. The plasma samples were stored in multiple aliquots and thawed only  
168 once.

### 169 **Biomarker assessments**

170 Plasma markers were assessed in all three groups – patients with persistent headache after  
171 COVID-19 infection (n=29), patients with persistent headache after the COVID-19 vaccine  
172 (n=31), and healthy controls (n=16). The participants had blood samples drawn when they  
173 were included in the study. Additionally, 6-month follow-up blood sampling was done in the  
174 headache groups. Plasma levels of APP (Cat# DY850), PZP (Cat# DY8280-05), CTSL (Cat#  
175 DY952), and SAA1 (Cat# DY3019-05) were measured by enzyme-linked immunosorbent  
176 assay (ELISA) using commercially available antibodies (R&D Systems, Minneapolis, MN) in  
177 a 384-format using a combination of a SELMA pipetting robot (Analytik Jena AG, Jena,  
178 Germany) and a BioTek dispenser/washer (BioTek Instruments, Winooski, VT). Absorption  
179 was read at 450 nm by using an EIA plate reader (BioTek Instruments) with wavelength  
180 correction set to 540 nm. Intra- and inter-assay coefficients of variation for these analyses  
181 were all <10%.

182

### 183 **Ethics approval**

184 This study was conducted in accordance with the Helsinki Declaration as revised in 2013.  
185 Ethical approval for this study was obtained from The Norwegian South-Eastern Ethical  
186 Committee (152727 NNC, 351097 CovaxHEAD). Written informed consent was obtained  
187 from all subjects before inclusion into the study.

188

## 189 **Statistics**

190 Statistical Package for Social Science (IBM SPSS Inc., version 29 for Windows) was used for  
191 statistical analysis. Differences in patient characteristics were tested using the Chi-square test  
192 or Fisher's exact test for categorical variables, and the Mann-Whitney U test for continuous  
193 variables. Prevalence of characteristics (frequency and percentages) were calculated for each  
194 group. A two-sided p-value of <0.05 was deemed statistically significant.

195

## 196 **Results**

### 197 **Characteristics and headache phenotypes in the study group**

198 Demographics such as age, gender and co-morbidities are shown in Table 1. There was equal  
199 age and sex distribution in both headache groups (i.e., persistent headache following COVID-  
200 19 or SARS-CoV-2 vaccination, respectively) with 3 out of 4 participants being female.  
201 Comorbidity of frequent diseases, such as pre-existing migraine, allergies, anxiety, and  
202 depression were common in both groups. Few had cardiovascular or metabolic disorders.  
203 One-third of the patients with persistent headache after COVID-19 infection was hospitalised  
204 in the acute phase of the infection. In the group with a persistent headache after SARS-CoV-2  
205 vaccine 17 (54.8%) reported previous COVID-19 at baseline, but importantly, without any  
206 persistent headache after the infection (Table 1). There was a high disability among the  
207 participants of both headache groups. More than two thirds of the participants with post  
208 COVID-19 and more than half the participants with headache post SARS-CoV-2 vaccination  
209 were on sick-leave due to the current symptoms at inclusion with only a modest reduction in  
210 the percentages on sick-leave at 6-month follow-up (72.4 % to 65.5 % and 58.1 % to 45.2 %,  
211 post COVID-19 and SARS-CoV-2 vaccination, respectively; Table 1). Cognitive symptoms  
212 and fatigue were common, but not dominating (see Methods), in both headache groups (Table  
213 1).

214

215 Table 1. Demographic and clinical characteristics at inclusion

Characteristics	Headaches after COVID- 19 n = 29	Headaches SARS-CoV-2 vaccine n = 31	P value
Mean age at inclusion, (SD)	43.5 (11.2)	43.8 (12.4)	0.836
Female, n (%)	22 (75.9)	24 (77.4)	0.862
Education			
Secondary school n (%)	2 (6.8)	7 (22.6)	0.193
College/university ≤ 4 years, n (%)	14 (48.3)	12 (38.7)	
College/university > 4 years, n (%)	13 (44.8)	12 (38.7)	
Hospitalisation during COVID-19, n (%)	9 (31.0)	3 (9.7)	
Smoking, n (%)	1 (4.4)	2 (6.5)	0.610
Pre-existing migraine, n (%)	11 (31.0)	12 (38.7)	0.871
Comorbidities			
Allergy, n (%)	16 (55.1)	13 (41.9)	0.240
Asthma, n (%)	2 (6.9)	6 (19.4)	0.150
Depression, n (%)	8 (27.6)	10 (32.3)	0.759
Anxiety, n (%)	7 (24.1)	13 (41.9)	0.170
Diabetes, n (%)	0	1 (3.3)	0.330
Cardiovascular disease, n (%)	0	1 (3.3)	0.330
Stroke, n (%)	0	0	
Associated symptoms			
Fatigue, n (%)	22 (75.9)	20 (64.5)	0.204
Subjective cognitive symptoms, n (%)	22 (75.9)	17 (54.8)	0.119
Sick leave at first visit, n (%)	21 (72.4)	18 (58.1)	0.244
Sick leave at 6-month follow-up, n (%)	19 (65.5)	14 (45.2)	0.207

216

217 **Biomarkers in relation to post-COVID-19 headache and headache following SARS-**

218 **CoV-2 vaccination**



219 At both inclusion and after 6 months, we found a strong and persistent upregulation of APP in  
220 patients with headache after COVID-19 as compared to individuals with vaccine induced  
221 headache and healthy controls (Figure 1A). There was also upregulation of CTSL in patients  
222 with headache after COVID-19 as compared to individuals with vaccine induced headache  
223 and healthy controls at inclusion, but these differences were not seen at 6 months follow-up  
224 (Figure 1B). In contrast, plasma levels of PZP were elevated in both headache groups as  
225 compared to healthy controls at inclusion and after 6 months follow-up (Figure 1C). As for  
226 SAA1, being a classical acute phase protein reflecting inflammation, there were no  
227 differences between the two headache groups and healthy controls either at baseline or during  
228 follow-up (Figure 1D). Finally, whereas post-COVID-19 symptoms have been related to  
229 disease severity during the acute phase,<sup>18</sup> we found no differences in the actual biomarkers  
230 between those who were hospitalized and those who were not hospitalized during the acute  
231 phase of COVID-19 (data not shown).

232

### 233 **Biomarker levels in relation to associated fatigue and cognitive symptoms**

234 There was a significant upregulation of APP among participants with accompanying cognitive  
235 symptoms in the group with persistent headache after COVID-19, but this pattern was not  
236 seen in those with headache after SARS-CoV-2 vaccination (Figure 2). Although those with  
237 fatigue also had higher levels of APP compared with those without, the difference did not  
238 reach statistical significance (Figure 2). As for PZP, CTSL, there were no differences between  
239 those with or without associated cognitive symptoms or fatigue, neither in the COVID-19 nor  
240 the SARS-CoV-2 group (data not shown).

241

### 242 **Discussion**

243 Persistent headache has been reported following acute COVID-19 disease and to some degree  
244 also after SARS-CoV-2 vaccination.<sup>1,3</sup> In the present study, we report higher plasma levels of  
245 APP in patients with persistent headache after COVID-19 disease, but not in patients with  
246 persistent headache following SARS-CoV-2 vaccination, compared to healthy controls.  
247 Remarkably, elevated APP persisted at 6 months follow-up and was associated with  
248 accompanying cognitive symptoms. Notably, plasma levels of PZP were higher in both  
249 headache groups as compared to controls with a similar pattern after 6 months follow-up. This  
250 is to the best of our knowledge, the first report that relates proteins involved in amyloid  
251 formation in persistent headache following COVID-19 disease, and for PZP, also in  
252 individuals with persistent headache after SARS-CoV-2 vaccination.

253 As depicted in Figure 3, our data point to plausible mechanism of serum APP and PZP  
254 proteins in relation to COVID-19 and SARS-CoV-2 vaccine induced headache. In brief, APP  
255 is produced by neurons and proteolysis by different secretases may produce a soluble (s)  
256 fragment, sAPP, and release of the neurotoxic A $\beta$  peptide. SARS-CoV-2 infection may  
257 increase APP expression via the ACE2 receptor<sup>19, 20</sup> and APP promotes cellular entry of the  
258 virus enhancing A $\beta$ -associated pathology.<sup>10</sup> The A $\beta$  peptide may accumulate and form  
259 amyloid plaques<sup>21</sup> leading to activation of astrocytes and microglia and promote  
260 neuroinflammation by different mechanisms<sup>22</sup> with potential effect on headache symptoms.<sup>23</sup>

261 Increased levels of APP is reported as marker for preclinical Alzheimer disease,  
262 however, this protein biological function is beyond that of amyloid formation<sup>24</sup> and elevated  
263 levels has been found in various metabolic and cardiovascular disorders.<sup>25</sup> In the present  
264 study, however, few or none had such clinically verified co-morbidities. However, we found  
265 significant upregulation of APP among participants with accompanying cognitive symptoms  
266 in the group with persistent headache after COVID-19 compared to those without cognitive  
267 symptoms. Moreover, network analyses of SARS-CoV-2 infection in brain microvascular  
268 endothelial cells suggested increased expression of APP.<sup>19</sup> In a previous study of patients with  
269 COVID-19 associated neurological syndromes, signs of impaired amyloid processing was  
270 found with significantly reduced soluble amyloid precursor protein in CSF from patients  
271 compared to controls.<sup>26</sup> However, this study was dominated of patients with severe  
272 neurological diseases such as Guillain Barre syndrome and encephalopathy and only one  
273 patient was described with central pain syndrome.<sup>26</sup> Furthermore, cognitive symptoms were  
274 not reported. At present, however, the reason for and the clinical consequences of the raised  
275 APP in patients with persistent headache following COVID-19 disease is elusive and follow-  
276 up studies are clearly needed.

277 In contrast to APP, plasma levels of PZP were persistently elevated in both headache  
278 groups, i.e., prolonged headache following both COVID-19 and SARS-CoV-2 vaccination.  
279 The reason for this pattern is so far unclear. PZP is known to promote a beneficial  
280 immunosuppression during pregnancy to avoid rejection of the foetus. More recently,  
281 increased PZP levels has been found during airway infections<sup>12</sup> and have been suggested as a  
282 marker of certain cancers.<sup>27</sup> Moreover, previous studies with mouse models have indicated  
283 that APP can increase the entry of the SARS-Cov-2 virus into cells whereas PZP has been  
284 described to inhibit amyloid aggregation.<sup>28</sup> Since APP was lower in the vaccine group than  
285 the COVID-19 group, one intriguing hypothesis is that PZP were able to inhibit amyloid  
286 aggregation at a higher degree in the vaccine group than in the COVID-19 group. However,

287 PZP has also been reported to stabilize misfolding proteins like amyloid  $\beta$  protein, and the  
288 role of PZP in amyloid formation is still not clear.<sup>28</sup>

289 The strengths of this study were the comprehensive examinations of the participants  
290 done by headache specialists with precise phenotyping of the headache syndromes and the  
291 strong multidisciplinary collaboration. The major limitations were the lack of CSF samples in  
292 both headache groups. Moreover, we lack parallel samples from CSF and measurements of  
293 the actual protein in individuals that have undergone COVID-19 and SARS-CoV-2  
294 vaccination without the development of persistent headache.

295 In summary, altered plasma levels of soluble markers that potentially could reflect  
296 changes in amyloid processing was found in patients with persistent headache after SARS-  
297 CoV-2 vaccine and particular in those with persistent headache after COVID-19 disease with  
298 association to cognitive symptoms. Future and larger studies that also include CSF samples  
299 are needed to further elaborate the clinical consequences of these findings.

300

301 **Acknowledgement:** We thank Marcus Boateng for registering data and Katrine Persgård  
302 Lund and Azita Rashidi for the processing of blood biomarkers.

## 303 References

- 304 1. Caronna E, van den Hoek TC, Bolay H, et al. Headache attributed to SARS-CoV-2  
305 infection, vaccination and the impact on primary headache disorders of the COVID-19  
306 pandemic: A comprehensive review. *Cephalalgia* 2023;43:3331024221131337.
- 307 2. Shen Q, Joyce EE, Ebrahimi OV, et al. COVID-19 illness severity and 2-year  
308 prevalence of physical symptoms: an observational study in Iceland, Sweden, Norway and  
309 Denmark. *Lancet Reg Health Eur* 2023;35:100756.
- 310 3. Atalar AC, Acarli ANO, Baykan B, et al. COVID-19 vaccination-related headache  
311 showed two different clusters in the long-term course: a prospective multicenter follow-up  
312 study (COVA-Head Study). *J Headache Pain* 2023;24:132.
- 313 4. Files JK, Sarkar S, Fram TR, et al. Duration of post-COVID-19 symptoms is  
314 associated with sustained SARS-CoV-2-specific immune responses. *JCI Insight* 2021;6.
- 315 5. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-  
316 CoV-2. *Nature* 2021;591:639-644.
- 317 6. Garces KN, Cocores AN, Goadsby PJ, Monteith TS. Headache After Vaccination: An  
318 Update on Recent Clinical Trials and Real-World Reporting. *Curr Pain Headache Rep*  
319 2022;26:895-918.
- 320 7. Hervé CL, B.; Del Giudice, G.; Didierlaurent, AM.; Tavares Da Silva, F. . The how's  
321 and what's of vaccine reactogenicity. *NPJ Vaccines* 2019;4.
- 322 8. Li HX, X.; Ren, H.; Xu, L.; Zhao, L.; Chen, X.; Long, H.; Wang, Q.; Wua, Q. Serum  
323 Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. *J Infect*  
324 2020;80:646–655.
- 325 9. Orobets KS, Karamyshev AL. Amyloid Precursor Protein and Alzheimer's Disease. *Int*  
326 *J Mol Sci* 2023;24.
- 327 10. Chen J, Chen J, Lei Z, et al. Amyloid precursor protein facilitates SARS-CoV-2 virus  
328 entry into cells and enhances amyloid-beta-associated pathology in APP/PS1 mouse model of  
329 Alzheimer's disease. *Transl Psychiatry* 2023;13:396.
- 330 11. Shao J, Jin Y, Shao C, Fan H, Wang X, Yang G. Serum exosomal pregnancy zone  
331 protein as a promising biomarker in inflammatory bowel disease. *Cell Mol Biol Lett*  
332 2021;26:36.
- 333 12. Finch S, Shoemark A, Dicker AJ, et al. Pregnancy Zone Protein Is Associated with  
334 Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in  
335 Bronchiectasis. *Am J Respir Crit Care Med* 2019;200:992-1001.
- 336 13. Villar M, Urrea JM, Rodriguez-Del-Rio FJ, et al. Characterization by Quantitative  
337 Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19  
338 Symptomatology. *Front Immunol* 2021;12:730710.
- 339 14. Ijsselstijn L, Dekker LJ, Stingl C, et al. Serum levels of pregnancy zone protein are  
340 elevated in presymptomatic Alzheimer's disease. *J Proteome Res* 2011;10:4902-4910.
- 341 15. Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2  
342 infection in humans and humanized mice and is a promising target for new drug development.  
343 *Signal Transduct Target Ther* 2021;6:134.
- 344 16. Wang H, Sang N, Zhang C, Raghupathi R, Tanzi RE, Saunders A. Cathepsin L  
345 Mediates the Degradation of Novel APP C-Terminal Fragments. *Biochemistry* 2015;54:2806-  
346 2816.
- 347 17. Beghi E, Moro E, Davidescu EI, et al. Comparative features and outcomes of major  
348 neurological complications of COVID-19. *Eur J Neurol* 2023;30:413-433.
- 349 18. Headache Classification Committee of the International Headache Society (IHS) The  
350 International Classification of Headache Disorders, 3rd edition. *Cephalalgia* 2018;38:1-211.

- 351 19. Camacho RC, Alabed S, Zhou H, Chang SL. Network Meta-analysis on the Changes  
352 of Amyloid Precursor Protein Expression Following SARS-CoV-2 Infection. *J Neuroimmune*  
353 *Pharmacol* 2021;16:756-769.
- 354 20. Caradonna A, Patel T, Toleska M, Alabed S, Chang SL. Meta-Analysis of APP  
355 Expression Modulated by SARS-CoV-2 Infection via the ACE2 Receptor. *Int J Mol Sci*  
356 2022;23.
- 357 21. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease.  
358 *Annu Rev Neurosci* 2011;34:185-204.
- 359 22. Di Benedetto G, Burgaletto C, Bellanca CM, Munafo A, Bernardini R, Cantarella G.  
360 Role of Microglia and Astrocytes in Alzheimer's Disease: From Neuroinflammation to Ca(2+)  
361 Homeostasis Dysregulation. *Cells* 2022;11.
- 362 23. Kursun O, Yemisci M, van den Maagdenberg A, Karatas H. Migraine and  
363 neuroinflammation: the inflammasome perspective. *J Headache Pain* 2021;22:55.
- 364 24. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. *Mol*  
365 *Neurodegener* 2006;1:5.
- 366 25. Guo Y, Wang Q, Chen S, Xu C. Functions of amyloid precursor protein in metabolic  
367 diseases. *Metabolism* 2021;115:154454.
- 368 26. Ziff OJ, Ashton NJ, Mehta PR, et al. Amyloid processing in COVID-19-associated  
369 neurological syndromes. *J Neurochem* 2022;161:146-157.
- 370 27. Huang J, Xu Y, Chen Y, et al. Revisiting the role of pregnancy zone protein (PZP) as a  
371 cancer biomarker in the immunotherapy era. *J Transl Med* 2024;22:500.
- 372 28. Cater JH, Kumita JR, Zeineddine Abdallah R, et al. Human pregnancy zone protein  
373 stabilizes misfolded proteins including preeclampsia- and Alzheimer's-associated amyloid  
374 beta peptide. *Proc Natl Acad Sci U S A* 2019;116:6101-6110.
- 375

376 **Figure legends**

377 **Figure 1.** Plasma levels of **A.** Amyloid Precursor Protein (APP), **B.** Cathepsin L., **C.**  
378 Pregnancy Zone Protein (PZP) and **D.** Serum Amyloid A (SAA1) in healthy controls (HC)  
379 (n=16), participants with persistent headache after SarsCoV-2 vaccine (COvax) (n=31) and  
380 participants with persistent headache after COVID-19 (C19) (n=29).

381

382 **Figure 2.** Plasma levels of Amyloid Precursor Protein (AAP) in relation to cognitive  
383 symptoms and fatigue in those with persistent headache after SARS-CoV-2 vaccine (COvax)  
384 or COVID-19 (C19).

385

386 **Figure 3.** Possible mechanisms of soluble Amyloid Precursor Protein (sAPP) and Pregnancy  
387 Zone Protein (PZP) in relation to COVID-19 and SARS-CoV-2 vaccination associated  
388 headache. The authors wish to acknowledge SERVIER Medical Art ([www.servier.fr](http://www.servier.fr)) for use  
389 of their medical art kits when making the illustration in the article.

390 **Study funding:** Supported by Oslo University Hospital and the Southern and Eastern Norway  
 391 Regional Health Authority (2021051).

392 **Acknowledgement:** We thank Marcus Boateng for registering data and Katrine Persgård  
 393 Lund and Azita Rashidi with the sampling of blood biomarkers.

394 **Statistical Analysis:** Thor Ueland and Anne Hege Aamodt

395 **Disclosure**

396 **Conflicts of interest:** The authors report no disclosures relevant to this study.

397 A.H. Aamodt has received honoraria for advice or lecturing from Pfizer Allergan, Teva,

398 Novartis, Roche, Lundbeck and Teva and research grant from Boehringer Ingelheim.

399 Anne Christine Poole: lecturing, advisory boards and/or clinical studies: Abbvie, Lundbeck,

400 Pfizer, Novartis, Teva, Eli Lilly

401

Co-investigators	Affiliations
Øyvind Torkildsen	Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway
Vojtech Novotny	Department of Neurology, Haukeland University Hospital, Bergen, Norway
Heidi Øyen Flemmen	Department of Neurology, Telemark Hospital Trust, Skien, Norway
Hilde Karen Ofte	Department of Neurology, Nordlandssykehuset, Bodø, Norway
Christian Samsonsen	Department of Neurology of Clinical Neurophysiology, St. Olav Hospital, Trondheim, Norway
Barbara Ratajczak-Tretel	Department of Neurology, Østfold Hospital Trust, Sarpsborg, Norway
Anette Huuse Farmen	Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway
Per Selnes	Department of Neurology, Akershus University Hospital, Nordbyhagen, Norway and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
Stein Andersson	Department of Psychology, University of Oslo, Oslo, Norway
Erlend Bøen	Unit for Psychosomatics and C-L psychiatry for adults, Oslo University Hospital, Oslo, Norway

Siv Elin Pignatiello	Unit for Psychosomatics and C-L psychiatry for adults, Oslo University Hospital, Oslo, Norway and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
----------------------	---

402

403







